The real-world treatment of hemorrhages associated with dabigatran and rivaroxaban

Critical Pathways in Cardiology

Volumn 14, Issue 2, 2015, Pages 53-61

  Pahs, Lesley ^a   Beavers, Craig ^a   Schuler, Patricia ^b  

^a CENTENNIAL MEDICAL CENTER   (United States)

^b Roper St Francis Healthcare   (United States)

Author keywords

anticoagulants; cardiology; critical care; hematology; prescribing patterns

Indexed keywords

ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; AMIODARONE; BLOOD CLOTTING FACTOR 9 COMPLEX; BOSENTAN; CLOPIDOGREL; DABIGATRAN; DILTIAZEM; DRONEDARONE; ERLOTINIB; ESCITALOPRAM; FENOFIBRATE; FLUOXETINE; FRESH FROZEN PLASMA; HEMOGLOBIN; INOTROPIC AGENT; IRON SACCHARATE; LEVOTHYROXINE; METFORMIN; OXYCODONE; PANTOPRAZOLE; PHYTOMENADIONE; PREDNISONE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; SERTRALINE; VENLAFAXINE; VITAMIN K GROUP; WARFARIN; ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; COAGULATING AGENT; CRYOPRECIPITATE COAGULUM; FIBRINOGEN; PROTHROMBIN COMPLEX CONCENTRATES; RECOMBINANT PROTEIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CRYOPRECIPITATE; DEATH; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPISTAXIS; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMOSTASIS; HIP REPLACEMENT; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPOTHERMIA; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INCONTINENCE; ISCHEMIC CARDIOMYOPATHY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NEW-ONSET ATRIAL FIBRILLATION; PAROXYSMAL ATRIAL FIBRILLATION; PATIENT MONITORING; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SICK SINUS SYNDROME; THROMBOCYTE TRANSFUSION; THROMBOELASTOGRAPHY; TRANSIENT ISCHEMIC ATTACK; VENOUS THROMBOEMBOLISM; VERY ELDERLY; VOMITING; CHEMICALLY INDUCED; CLINICAL TRIAL; COHORT ANALYSIS; INTRACRANIAL HEMORRHAGES; PLASMA;

AGED; AGED, 80 AND OVER; ANTITHROMBINS; BLOOD COAGULATION FACTORS; COAGULANTS; COHORT STUDIES; DABIGATRAN; EPISTAXIS; ERYTHROCYTE TRANSFUSION; FACTOR VIIA; FACTOR VIII; FEMALE; FIBRINOGEN; GASTROINTESTINAL HEMORRHAGE; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; PLASMA; PLATELET TRANSFUSION; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIVAROXABAN;

EID: 84966525948     PISSN: 1535282X     EISSN: 15352811     Source Type: Journal    
DOI: 10.1097/HPC.0000000000000042     Document Type: Article

References (26)

1. Connolly SJ, Ezekowitz MD, Yusuf S, RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009 361 1139 1151
2. Connolly SJ, Ezekowitz MD, Yusuf S, Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators Newly identified events in the RE-LY trial. N Engl J Med 2010 363 1875 1876
3. Granger CB, Alexander JH, McMurray JJ, ARISTOTLE Committees and Investigators Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011 365 981 992
4. Patel MR, Mahaffey KW, Garg J, ROCKET AF Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011 365 883 891
5. Dabigatran [package insert] 2010 Ridgefield, CT Boehringer Ingelheim Pharmaceuticals, Inc
6. Rivaroxaban [package insert] 2011 Titusville, NJ Janssen Pharmaceuticals, Inc
7. Apixaban [package insert] 2012 Princeton, NJ Bristol-Myers Squibb Company
8. Phase 2 healthy volunteer study to evaluate the ability of PRT064445 to reverse the effects of several blood thinner drugs on laboratory tests [Internet]. 2012 Tempe (AZ) Portola Pharmaceuticals. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01758432?term=prt064445&rank=1. Accessed June 11, 2013
9. Schiele F, van Ryn J, Canada K, A specific antidote for dabigatran: functional and structural characterization. Blood 2013 121 3554 3562
10. Antidote for new oral anticoagulants-PER977 [Internet]. Danbury (CT): Perosphere Inc.-The drug rescue company; 2013. Available at: http://www.perosphere.com/content/drug/drugcandidates.htm. Accessed November 22, 2013
11. Douxfils J, Mullier F, Loosen C, Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 2012 130 956 966
12. Douxfils J, Mullier F, Robert S, Impact of dabigatran on a large panel of routine or specific coagulation assays. Thromb Haemost 2012 107 985 997
13. Eerenberg ES, Kamphuisen PW, Sijpkens, Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011 124 1573 1579
14. Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E, Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. PLoS One 2013 8 e78696
15. Kaatz S, Kouides PA, Garcia DA, Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012 87 Suppl 1) S141 S145
16. Mani H, Wagner C, Lindhoff-Last E, Influence of New Anticoagulants on Coagulation Tests 2011 Siemens Healthcare Diagnostics 12 p. Available at: http://www.healthcare.siemens.com/siemens-hwem-hwem-ssxa-websites-context-root/wcm/idc/siemens-hwem-hwem-ssxa-websites-context-root/wcm/idc/groups/public/@global/@lab/documents/download/mdaw/nzqx/∼edisp/110166-xc1-4-new-antcglnts-wp-final-single-00453697.pdf. Accessed September 5, 2012
17. Marlu R, Hodaj E, Paris A, Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012 108 217 224
18. Miyares MA, Davis K, Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. Am J Health Syst Pharm 2012 69 1473 1484
19. Dager WE, Developing a management plan for oral anticoagulant reversal. Am J Health Syst Pharm 2013 70 10 Suppl 1 S21 S31
20. Miesbach W, Seifried E, New direct oral anticoagulants-current therapeutic options and treatment recommendations for bleeding complications. Thromb Haemost 2012 108 625 632
21. Liesenfeld KH, Lehr T, Dansirikul C, Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with nonvalvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011 9 2168 2175
22. Rivaroxaban for the Prevention of Stroke and Non-Central Nervous System (CNS) Systemic Embolism in Patients with Atrial Fibrillation 2011 Aug Johnson & Johnson Pharmaceutical Research & Development 222. p. Report No.: EDMS-ERI-24510755:2.0
23. Stangier J, Rathgen K, Stähle H, Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010 49 259 268
24. van Ryn J, Stangier J, Haertter S, Dabigatran etexilate-A novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010 103 1116 1127
25. Stöllberger C, Finsterer J, Concerns about the use of new oral anticoagulants for stroke prevention in elderly patients with atrial fibrillation. Drugs Aging 2013 30 949 958
26. Dager WE, King JH, Regalia RC, Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy 2006 26 1091 1098